Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...

BRAF V600E mutations are common in different tumor ... including FISH- and real-time PCR-based methods. MAPK Pathway as Potential Therapeutic Target in Clinical Neuro-oncology Given the frequent ...

Nat Clin Pract Endocrinol Metab. 2006;2(4):180-181. The fact that PTC is associated with mutually exclusive alterations to MAPK pathway effectors offers intriguing therapeutic opportunities.

Drug major Pfizer Inc. (PFE) announced Monday positive topline results from the progression-free survival or PFS analysis of the ...

Pfizer Inc. today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of BRAFTOVI® (encorafenib) in combination with cetuximab ...

Three trials presented at ASCO GI 2025 will change practice and improve the treatment of colorectal cancer, according to experts.

Braftovi is a small molecule inhibitor of proteins with the BRAF V600E mutation, which can lead to activation of signaling pathways that drive certain cancers, including colorectal cancer.

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant metastatic colorectal cancer (mCRC), according to the BREAKWATER trial. The study ...

Pasithea Therapeutics (KTTA) announced that the external Safety Review Committee recommended that the Company’s Phase 1 clinical trial of ...

Pfizer’s BREAKWATER trial of Braftovi combo regimen demonstrates improved response in patients with BRAF V600E-mutant metastatic colorectal cancer: New York Tuesday, January 28, ...

Pfizer Inc. today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, ...